Display options
Share it on

Metabolites. 2021 Oct 30;11(11). doi: 10.3390/metabo11110752.

The Impact of Histological Annotations for Accurate Tissue Classification Using Mass Spectrometry Imaging.

Metabolites

Juliana Pereira Lopes Gonçalves, Christine Bollwein, Anna Melissa Schlitter, Benedikt Martin, Bruno Märkl, Kirsten Utpatel, Wilko Weichert, Kristina Schwamborn

Affiliations

  1. Institute of Pathology, School of Medicine, Technical University of Munich, Trogerstraße 18, 81675 Munich, Germany.
  2. German Cancer Consortium (DKTK), Partner Site Munich, 80336 Munich, Germany.
  3. General Pathology and Molecular Diagnostics, Medical Faculty, University Hospital of Augsburg, 86156 Augsburg, Germany.
  4. Institute of Pathology, University of Regensburg, 93053 Regensburg, Germany.
  5. Comprehensive Cancer Center Munich (CCCM), Marchioninistraße 15, 81377 Munich, Germany.

PMID: 34822410 PMCID: PMC8624953 DOI: 10.3390/metabo11110752

Abstract

Knowing the precise location of analytes in the tissue has the potential to provide information about the organs' function and predict its behavior. It is especially powerful when used in diagnosis and prognosis prediction of pathologies, such as cancer. Spatial proteomics, in particular mass spectrometry imaging, together with machine learning approaches, has been proven to be a very helpful tool in answering some histopathology conundrums. To gain accurate information about the tissue, there is a need to build robust classification models. We have investigated the impact of histological annotation on the classification accuracy of different tumor tissues. Intrinsic tissue heterogeneity directly impacts the efficacy of the annotations, having a more pronounced effect on more heterogeneous tissues, as pancreatic ductal adenocarcinoma, where the impact is over 20% in accuracy. On the other hand, in more homogeneous samples, such as kidney tumors, histological annotations have a slenderer impact on the classification accuracy.

Keywords: histological annotations; mass spectrometry imaging; on-tissue analysis; proteomics; supervised classification

References

  1. Clin Lab Med. 2021 Jun;41(2):173-184 - PubMed
  2. Methods. 2018 Dec 1;151:21-27 - PubMed
  3. Annu Rev Pathol. 2006;1:119-50 - PubMed
  4. Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588 - PubMed
  5. Proteomics. 2014 Apr;14(7-8):965-72 - PubMed
  6. Nat Rev Cancer. 2001 Nov;1(2):151-7 - PubMed
  7. Mol Cancer. 2018 Jun 14;17(1):95 - PubMed
  8. Sci Rep. 2017 Dec 4;7(1):16878 - PubMed
  9. J Clin Oncol. 2004 Aug 15;22(16):3408-19 - PubMed
  10. Anal Chem. 2020 Jan 7;92(1):1301-1308 - PubMed
  11. Mol Cell Proteomics. 2016 Mar;15(3):1072-82 - PubMed
  12. Adv Cancer Res. 2017;134:1-26 - PubMed
  13. Metabolites. 2021 Apr 18;11(4): - PubMed
  14. Adv Cancer Res. 2017;134:27-66 - PubMed
  15. Nat Protoc. 2016 Aug;11(8):1428-43 - PubMed
  16. Clin Chem Lab Med. 2020 Jun 25;58(6):914-929 - PubMed
  17. Anal Chem. 2021 Aug 3;93(30):10584-10592 - PubMed
  18. Proteomics Clin Appl. 2019 Jan;13(1):e1800029 - PubMed
  19. Nat Med. 2019 Aug;25(8):1301-1309 - PubMed

Publication Types